Physician profile
Bryan D Chastain
NPI 1023019429
$1,836.66
in general payments reported to CMS, 2019-2025
24 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $128 · 2021: $51.65 · 2022: $65.72 · 2023: $400 · 2024: $508 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $320.82 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $300.27 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Novartis Pharmaceuticals Corporation | $238.63 | 2019-2025 | |
| Abbvie INC. | $124.49 | 2023-2024 | Vraylar, Ubrelvy |
| Irhythm Technologies, INC. | $109.72 | 2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $107.26 | 2020-2024 | Breztri, Airsupra, Farxiga |
| Radius Health, INC. | $102.26 | 2019-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $65.29 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $59.21 | 2023-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $55.46 | 2025 | Rexulti |
| Pfizer INC. | $48.29 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.15 | 2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.44 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $37.83 | 2020-2021 | |
| Mylan Specialty L.P. | $37.19 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.11 | 2024-2025 | Repatha, Otezla, Repatha |
| Azurity Pharmaceuticals, INC. | $17.77 | 2023 | Horizant |
| Exact Sciences Corporation | $16.05 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.02 | 2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $15.51 | 2019 | |
| Eisai INC. | $14.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.11 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Chastain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.